@entity1090 appears to have a beneficial effect in several areas of cognitive function in @entity161 @entity1 . In previous studies, however, the clinical characteristics of the subjects differed between studies, and were heterogeneous even in single study. Most of the subjects were previously exposed to different kinds of neuroleptics and some of them were treatment-resistant. The aim of this study is to evaluate the effect of @entity1090 on attention and information processing in a homogeneous subgroup of @entity161 @entity1 , i.e. drug-na  ve first-episode inpatients. In the @entity1 group (n=17), cognitive tests and clinical assessments were performed before and after 8 weeks of @entity1090 treatment. The same cognitive tests were administered to the control group (n=24). The delay between test and retest was 8 weeks. Before treatment, the @entity1 group performed significantly worse than control group on the tests measuring continuous attention, vigilance, and the speed of information processing. After treatment (the average dose of @entity1090 was 7.3mg/day), in spite of significant improvement of the clinical symptoms, the @entity1 did not show any significant improvement or worsening in most of the items of these tests. The control group did not show any practice effect. These results suggest that first-episode @entity161 @entity1 have deficits in sustained attention and vigilance to visual stimuli, as well as the speed of information processing to visual and auditory stimuli, and these deficits are unrelated to clinical symptoms and remain stable during the early phase of treatment. This study did not receive pharmaceutical company financial support.

Effects of XXXX on information processing and attention in first-episode @entity161 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenic'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone', 'Risperidone']
@entity1090 :: (MESH:D018967,Chemical) :: ['risperidone']
